Valuation: Soligenix, Inc.

Market Cap 8.71M 7.52M 7.08M 6.43M 12.08M 831M 12.29M 82.86M 32.38M 417M 32.67M 31.98M 1.39B P/E 2026 *
-0.73x
P/E 2027 * -1x
Enterprise Value 8.71M 7.52M 7.08M 6.43M 12.08M 831M 12.29M 82.86M 32.38M 417M 32.67M 31.98M 1.39B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
95.41%
Yield 2026 *
-
Yield 2027 * -
1 day+4.62%
1 week+1.63%
Current month+6.58%
1 month+10.79%
3 months+10.73%
6 months-63.44%
Current year-70.26%
1 week 0.38
Extreme 0.3775
0.4
1 month 0.35
Extreme 0.3454
0.4
Current year 0.28
Extreme 0.28
1.49
1 year 0.28
Extreme 0.28
6.23
3 years 0.28
Extreme 0.28
32
5 years 0.28
Extreme 0.28
295.2
10 years 0.28
Extreme 0.28
2,040
Manager TitleAgeSince
Chief Executive Officer 59 2006-07-31
Director of Finance/CFO 53 2019-09-10
Chief Tech/Sci/R&D Officer - 2026-06-10
Director TitleAgeSince
Chairman 59 2009-10-07
Director/Board Member 67 2009-02-28
Director/Board Member 80 2009-09-30
Date Insider Type Main position Quantity % Market Cap.
12/11/25 Free

Chief Executive Officer

200,000 1.9829%
12/11/25 Free

Chief Technology Officer

100,000 0.9915%
12/11/25 Free

Chief Technology Officer

10,000 0.0991%
Change 5-day change 1-year change 3-year change Capi.($)
+4.62%+1.63%-85.67%-94.93% 8.71M
-1.90%+2.85%+62.82%+104.13% 70.07B
-3.21%-4.32%+31.85%+58.98% 52.87B
-2.05%-5.61%-3.18%+449.22% 27.02B
-1.27%-1.57%+45.90%+8.25% 23.61B
+1.05%-0.62%-18.00%-13.77% 23.38B
+3.81%+20.97%+266.37%+531.28% 19.43B
+0.10%+1.40%+35.36%-19.94% 18.75B
-0.95%-3.52%+19.93%+594.00% 15.85B
+1.24%-5.23%+33.75%+140.34% 12.7B
Average +0.14%+1.81%+38.91%+175.76% 26.37B
Weighted average by Cap. -1.09%+0.55%+50.23%+165.24%

Financials

2026 *2027 *
Net sales - -
Net income -9.3M -8.04M -7.56M -6.87M -12.9M -887M -13.12M -88.51M -34.59M -445M -34.9M -34.16M -1.48B -10.1M -8.73M -8.21M -7.46M -14.01M -964M -14.25M -96.12M -37.57M -483M -37.91M -37.1M -1.61B
Net Debt - -
Logo Soligenix, Inc.
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
Employees
14
Date Price Change Volume
26-08-14 US$0.4000 +5.01% 333,465
26-08-13 US$0.3809 -2.33% 135,791
26-08-12 US$0.3900 +0.91% 127,093
26-08-11 US$0.3865 +2.38% 95,432
26-08-10 US$0.3775 -3.72% 144,706
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.4000USD
Average target price
1.375USD
Spread / Average Target
+243.75%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SNGX Stock